Patient education level as a predictor of survival in lung cancer clinical trials

Journal of Clinical Oncology

Volumn 26, Issue 25, 2008, Pages 4116-4123

  Herndon II, James E ^a   Kornblith, Alice B ^a   Holland, Jimmie C ^a   Paskett, Electra D ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE;

ADRENAL METASTASIS; ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER SURVIVAL; DYSPNEA; FEMALE; GENDER; HUMAN; LEUKOCYTE; LIVER METASTASIS; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PATIENT EDUCATION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SOCIOECONOMICS; THORAX PAIN; WEIGHT REDUCTION;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; EDUCATIONAL STATUS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SOCIAL CLASS; TREATMENT OUTCOME;

EID: 51649114276     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.16.7460     Document Type: Article

References (52)

1. House JS, Landis KR, Umberson D: Social relationships and health. Science 241:540-545, 1988
2. Marmot M: Social determinants of health equalities. Lancet 365:1099-1104, 2005
3. Lynch JW, Smith GD, Kaplan GA, et al: Income inequality and mortality: Importance to health of individual income, psychosocial environment, or material conditions. BMJ 320:1200-1204, 2000
4. Marmot M, Ryff CD, Bumpass LL, et al: Social inequalities in health: Next questions and converging evidence. Soc Sci Med 44:901-910, 1997
5. Marmot M, Wilkinson RG: Psychosocial and material pathways in the relations between income and health: A response to Lynch et al. BMJ 322:1233-1236, 2001
6. Marmot M: The influence of income on health: Views of an epidemiologist. Health Aff 21:31-46, 2002
7. Cella DF, Orav EJ, Kornblith AB, et al: Socioeconomic status and cancer survival. J Clin Oncol 9:1500-1509, 1991
8. Tammemagi CM, Neslund-Dudas C, Simoff M, et al: In lung cancer patients, age, race-ethnicity, gender and smoking predict adverse comorbidity, which in turn predicts treatment and survival. J Clin Epidemiol 57:597-609, 2004
9. Yabroff KR, Gordis L: Does stage at diagnosis influence the observed relationship between socioeconomic status and breast cancer incidence, case fatality, and mortality? Soc Sci Med 57:2265-2279, 2003
10. Cross CK, Harris J, Recht A: Race, socioeconomic status, and breast carcinoma in the U.S.: What have we learned from clinical studies? Cancer 95:1988-1999, 2002
11. Gorey KM, Kliewer E, Holowaty EJ, et al: An international comparison of breast cancer survival: Winnipeg, Manitoba and Des Moines, Iowa metropolitan areas. Ann Epidemiol 13:32-41, 2003
12. Mariotto A, Capocaccia R, Verdecchia A, et al: Projecting SEER cancer survival rates to the US: An ecological regression approach. Cancer Causes Control 13:101-111, 2002
13. Coleman MP, Babb P, Sloggett A, et al: Socioeconomic inequalities in cancer survival in England and Wales. Cancer 91:208-216, 2001
14. Vigano A, Bruera E, Jhangri GS, et al: Clinical survival predictors in patients with advanced cancer. Arch Intern Med 160:861-868, 2000
15. Mackillop WJ, Zhang-Salomons J, Groome PA, et al: Socioeconomic status and cancer survival in Ontario. J Clin Oncol 15:1680-1689, 1997
16. Goodwin JS, Samet JM, Hunt WC: Determinants of survival in older cancer patients. J Natl Cancer Inst 88:1031-1038, 1996
17. Stavraky KM, Skillings JR, Stitt LW, et al: The effect of socioeconomic status on the long-term outcome of cancer. J Clin Epidemiol 49:1155-1160, 1996
18. Dale W, Vijayakumar S, Lawlor EF, et al: Prostate cancer, race, and socioeconomic status: Inadequate adjustment for social factors in assessing racial differences. Prostate 29:271-281, 1996
19. Ou SHI, Zell JA, Ziogas A, et al: Prognostic factors for survival of stage I nonsmall cell lung cancer patients: A population-based analysis of 19,702 stage I patients in the California Cancer Registry from 1989 to 2003. Cancer 110:1532-1541, 2007
20. Sowah LA, Brahmer JR, Alberg AJ, et al: Census tract-level socioeconomic status as a determinant of survival in non-small cell lung cancer. Lung Cancer 46:S61-S62, 2004 (suppl)
21. Greenwald HP, Borgatta EF, McCorkle R, et al: Explaining reduced cancer survival among the disadvantaged. Milbank Q 72:215-238, 1996
22. Bouchardy C, Fioretta G, DePerrot M, et al: Determinants of long term survival. Cancer 86:2229-2237, 1999
23. Robbins AS, Yin D, Parikh-Patel A: Differences in prognostic factors and survival among white men and black men with prostate cancer, California, 1995-2004. Am J Epidemiol 166:71-78, 2007
24. Ortiz CA, Goodwin JS, Freeman JL: The effect of socioeconomic factors on incidence, stage at diagnosis and survival of cutaneous melanoma. Med Sci Monit 11:RA163-RA172, 2005
25. Lehto US, Ojanen M, Dyba T, et al: Baseline psychosocial predictors of survival in localized breast cancer. Br J Cancer 94:1245-1252, 2006
26. Dejardin O, Remontet L, Bouvier AM, et al: Socioeconomic and geographic determinants of survival of patients with digestive cancer in France. Br J Cancer 95:944-949, 2006
27. Abou-Jawde RM, Baz R, Walker E, et al: The role of race, socioeconomic status, and distance traveled on the outcome of African-American patients with multiple myeloma. Haematologica 91:1410-1413, 2006
28. Coker AL, Du XL, Fang S: Socioeconomic status and cervical cancer survival among older women: Findings from the SEER-Medicare linked data cohorts. Gynecol Oncol 102:278-284, 2006
29. Kaffashian F, Godward S, Davies T, et al: Socioeconomic effects on breast cancer survival: Proportion attributable to stage and morphology. Br J Cancer 89:1693-1696, 2003
30. Holland JC, Herndon J, Kornblith AB, et al: A sociodemographic data collection model for cooperative clinical trials. Proc Am Soc Clin Oncol 11:157, 1992 (abstr 445)
31. McClay EF, Bogart J, Herndon JE II, et al: A phase II trial evaluating the combination of cisplatin, etoposide, and radiation therapy with or without tamoxifen in patients with limited-stage small cell lung cancer: Cancer and Leukemia Group B study (9235). J Clin Oncol 28:81-90, 2005
32. Clamon G, Herndon J, Eaton W, et al: A feasibility study of extended chemotherapy for locally advanced non-small cell lung cancer: A phase II study of Cancer and Leukemia Group B. Cancer Invest 12:273-282, 1994
33. Kosty MP, Fleishman S, Herndon JE, et al: Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small cell lung cancer: A randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B. J Clin Oncol 12:1113-1120, 1994
34. Miller A, Herndon JE, Hollis DR, et al: Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive stage small-cell lung cancer: A randomized phase III study of the Cancer and Leukemia Group B (CALGB 9033). J Clin Oncol 13:1871-1879, 1995
35. Clamon G, Herndon J, Cooper R, et al: Radiosensitization with carboplatin for patients with unresectable stage 3 non-small cell lung cancer: A phase III trial of Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol 17:4-11, 1999
36. Herndon JE II, Fleishman S, Kornblith AB, et al: Is quality of life predictive of survival among patients with advanced non-small cell lung cancer? Cancer 85:333-340, 1999
37. Perry MC, Ihde DC, Herndon JE II, et al: Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532. Lung Cancer 28:63-68, 2000
38. Naughton MF, Shumaker SA, Herndon J, et al: Health-related quality of life in small-cell lung cancer patients: Quality of life companion to CALGB 9033. Qual Life Res 11:235-248, 2002
39. Lyss AP, Herndon J, Lynch TJ, et al: Novel doublets in extensive small cell lung cancer: A randomized phase II study of topotecan/cisplatin, paclitaxel/cisplatin, and paclitaxel/topotecan. Clin Lung Cancer 3:205-210, 2002
40. Akerley W, Herndon JE, Lyss AP, et al: Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small cell lung cancer: A limited-access study - CALGB 9534. Clin Lung Cancer 7:47-53, 2005
41. Vokes EE, Herndon JE II, Crawford J, et al: Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: Cancer and Leukemia Group B Study 9431. J Clin Oncol 20:4191-4198, 2002
42. Akerley W, Herndon JE, Egorin MJ, et al: Weekly, high-dose paclitaxel in advanced lung carcinoma. Cancer 97:2480-2486, 2003
43. Lilenbaum RC, Herndon JE II, List MA, et al: Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: The Cancer and Leukemia Group B (study 9730). J Clin Oncol 23:190-196, 2005
44. Agresti A: Categorical Data Analysis. New York, NY, Wiley, 1990
45. Motulsky H: Intuitive Biostatistics. New York, NY, Oxford University Press, 1995
46. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
47. Brookmeyer R, Crowley J: A confidence interval for the median survival time. Biometrics 38:29-41, 1982
48. Cox DR: Regression models and life tables (with discussion). J R Stat Soc B 34:187-220, 1972
49. Hosmer DW, Lemeshow S: Applied Logistic Regression. New York, NY, John Wiley & Sons, 1991
50. Hosmer DW, Lemeshow S: Applied Survival Analysis. New York, NY, John Wiley & Sons, 1999
51. Blackstock AW, Herndon JE II, Paskett ED, et al: Outcomes among African-American/non-African-American patients with advanced non-small-cell carcinoma: Report from the Cancer and Leukemia Group B. J Natl Cancer Inst 94:284-290, 2002
52. Blackstock AW, Herndon JE II, Paskett ED, et al: Similar outcomes between African American and non-African American patients with extensive-stage small-cell lung carcinoma: Report from the Cancer and Leukemia Group B. J Clin Oncol 24:407-412, 2006